Advertisement

Cancer Immunology, Immunotherapy

, Volume 63, Issue 2, pp 101–109 | Cite as

HER-2/neu vaccine-primed autologous T-cell infusions for the treatment of advanced stage HER-2/neu expressing cancers

  • Mary L. Disis
  • Yushe Dang
  • Andrew L. Coveler
  • Edmond Marzbani
  • Zhong C. Kou
  • Jennifer S. Childs
  • Patricia Fintak
  • Doreen M. Higgins
  • Jessica Reichow
  • James Waisman
  • Lupe G. Salazar
Original Article

Abstract

This phase I study evaluated the feasibility of expanding HER-2/neu (HER2) vaccine-primed peripheral blood T-cells ex vivo and assessed the safety of T-cell infusions. Eight patients with HER2+ treatment refractory metastatic cancers were enrolled. T-cells could be expanded to predefined parameters in seven patients (88 %). Ninety-two percent of adverse events were grade 1 or 2. Three of seven patients developed infusion-related inflammatory reactions at their disease sites. HER2-specific T-cells significantly increased in vivo compared to pre-infusion levels (p = 0.010) and persisted in 4/6 patients (66 %) over 70 days after the first infusion. Partial clinical responses were observed in 43 % of patients. Levels of T-regulatory cells in peripheral blood prior to infusion (p < 0.001), the level of HER2-specific T-cells in vivo (p = 0.030), and development of diverse clonal T-cell populations (p < 0.001) were associated with response. The generation of HER2 vaccine-primed autologous T-cells for therapeutic infusion is feasible and well tolerated. This approach provides a foundation for the application of T-cell therapy to additional solid tumor types.

Keywords

HER2 Adoptive T-cell therapy Phase I Clinical trial Vaccine 

Notes

Acknowledgments

This work was supported by Mr. and Mrs. Gavin Herbert, a grant from the Arnold and Mabel Beckman Foundation, Gateway, and NIHUL1TR000423. Most importantly, we acknowledge the invaluable contribution of the patients who volunteered to participate in this study.

Conflict of interest

Mary L. Disis is an inventor on patents held by the University of Washington that pertain to data presented in this manuscript. Zhong C. Kou is the founder of Biomed Immunotech, Inc. which holds proprietary technology on TCR analysis. All other authors do not have any conflicts to disclose.

Supplementary material

262_2013_1489_MOESM1_ESM.pdf (849 kb)
Supplementary material 1 (PDF 849 kb)

References

  1. 1.
    Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA et al (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23(10):2346–2357. doi: 10.1200/JCO.2005.00.240 PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF et al (2008) Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26(32):5233–5239. doi: 10.1200/JCO.2008.16.5449 PubMedCrossRefGoogle Scholar
  3. 3.
    Tjin EP, Konijnenberg D, Krebbers G, Mallo H, Drijfhout JW, Franken KL, van der Horst CM, Bos JD, Nieweg OE, Kroon BB et al (2011) T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy. Clin Cancer Res 17(17):5736–5747. doi: 10.1158/1078-0432.CCR-11-0230 PubMedCrossRefGoogle Scholar
  4. 4.
    Disis ML, Wallace DR, Gooley TA, Dang Y, Slota M, Lu H, Coveler AL, Childs JS, Higgins DM, Fintak PA et al (2009) Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol 27(28):4685–4692. doi: 10.1200/JCO.2008.20.6789 PubMedCrossRefGoogle Scholar
  5. 5.
    Dang Y, Knutson KL, Goodell V, dela Rosa C, Salazar LG, Higgins D, Childs J, Disis ML (2007) Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming. Clin Cancer Res 13(6):1883–1891. doi:  10.1158/1078-0432.CCR-06-2083 Google Scholar
  6. 6.
    Knutson KL, Disis ML (2004) IL-12 enhances the generation of tumour antigen-specific Th1 CD4 T cells during ex vivo expansion. Clin Exp Immunol 135(2):322–329. doi: 10.1111/j.1365-2249.2004.02360.x PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, Knutson KL, Schiffman K (2002) Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 20(11):2624–2632. doi: 10.1200/JCO.2002.06.171 PubMedCrossRefGoogle Scholar
  8. 8.
    Knutson KL, Schiffman K, Disis ML (2001) Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest 107(4):477–484. doi: 10.1172/JCI11752 PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Kou ZC, Puhr JS, Rojas M, McCormack WT, Goodenow MM, Sleasman JW (2000) T-Cell receptor Vbeta repertoire CDR3 length diversity differs within CD45RA and CD45RO T-cell subsets in healthy and human immunodeficiency virus-infected children. Clin Diagn Lab Immunol 7(6):953–959. doi: 10.1128/CDLI.7.6.953-959.2000 PubMedCentralPubMedGoogle Scholar
  10. 10.
    Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA (2010) Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18(4):843–851. doi: 10.1038/mt.2010.24 PubMedCrossRefGoogle Scholar
  11. 11.
    Okajima M, Wada T, Nishida M, Yokoyama T, Nakayama Y, Hashida Y, Shibata F, Tone Y, Ishizaki A, Shimizu M et al (2009) Analysis of T cell receptor Vbeta diversity in peripheral CD4 and CD8 T lymphocytes in patients with autoimmune thyroid diseases. Clin Exp Immunol 155(2):166–172. doi: 10.1111/j.1365-2249.2008.03842.x PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Langerak AW, Groenen PJ, Bruggemann M, Beldjord K, Bellan C, Bonello L, Boone E, Carter GI, Catherwood M, Davi F et al (2012) EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations. Leukemia 26(10):2159–2171. doi: 10.1038/leu.2012.246 PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Rapoport AP, Stadtmauer EA, Aqui N, Badros A, Cotte J, Chrisley L, Veloso E, Zheng Z, Westphal S, Mair R et al (2005) Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med 11(11):1230–1237. doi: 10.1038/nm1310 PubMedCrossRefGoogle Scholar
  14. 14.
    Stadtmauer EA, Vogl DT, Luning Prak E, Boyer J, Aqui NA, Rapoport AP, McDonald KR, Hou X, Murphy H, Bhagat R et al (2011) Transfer of influenza vaccine-primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: results of a randomized clinical trial. Blood 117(1):63–71. doi: 10.1182/blood-2010-07-296822 PubMedCrossRefGoogle Scholar
  15. 15.
    Powell DJ Jr, Dudley ME, Hogan KA, Wunderlich JR, Rosenberg SA (2006) Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion. J Immunol 177(9):6527–6539PubMedCentralPubMedGoogle Scholar
  16. 16.
    Cesana GC, DeRaffele G, Cohen S, Moroziewicz D, Mitcham J, Stoutenburg J, Cheung K, Hesdorffer C, Kim-Schulze S, Kaufman HL (2006) Characterization of CD4+ CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 24(7):1169–1177. doi: 10.1200/JCO.2005.03.6830 PubMedCrossRefGoogle Scholar
  17. 17.
    Disis ML, Knutson KL, Schiffman K, Rinn K, McNeel DG (2000) Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer. Breast Cancer Res Treat 62(3):245–252. doi: 10.1023/A:1006438507898 PubMedCrossRefGoogle Scholar
  18. 18.
    Zhu Z, Singh V, Watkins SK, Bronte V, Shoe JL, Feigenbaum L, Hurwitz AA (2013) High-avidity T cells are preferentially tolerized in the tumor microenvironment. Cancer Res 73(2):595–604. doi: 10.1158/0008-5472.CAN-12-1123 PubMedCrossRefGoogle Scholar
  19. 19.
    Brentville VA, Metheringham RL, Gunn B, Durrant LG (2012) High avidity cytotoxic T lymphocytes can be selected into the memory pool but they are exquisitely sensitive to functional impairment. PLoS ONE 7(7):e41112. doi: 10.1371/journal.pone.0041112 PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Comoli P, Pedrazzoli P, Maccario R, Basso S, Carminati O, Labirio M, Schiavo R, Secondino S, Frasson C, Perotti C et al (2005) Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J Clin Oncol 23(35):8942–8949. doi: 10.1200/JCO.2005.02.6195 PubMedCrossRefGoogle Scholar
  21. 21.
    Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, Almeida JR, Gostick E, Yu Z, Carpenito C et al (2011) A human memory T cell subset with stem cell-like properties. Nat Med 17(10):1290–1297. doi: 10.1038/nm.2446 PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR et al (2011) Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 17(13):4550–4557. doi: 10.1158/1078-0432.CCR-11-0116 PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Pilch H, Hohn H, Neukirch C, Freitag K, Knapstein PG, Tanner B, Maeurer MJ (2002) Antigen-driven T-cell selection in patients with cervical cancer as evidenced by T-cell receptor analysis and recognition of autologous tumor. Clin Diagn Lab Immunol 9(2):267–278. doi: 10.1128/CDLI.9.2.267-278.2002 PubMedCentralPubMedGoogle Scholar
  24. 24.
    Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang X, Southwood S, Robbins PF, Sette A, Appella E, Rosenberg SA (1995) Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 154(8):3961–3968PubMedGoogle Scholar
  25. 25.
    Yao X, Ahmadzadeh M, Lu YC, Liewehr DJ, Dudley ME, Liu F, Schrump DS, Steinberg SM, Rosenberg SA, Robbins PF (2012) Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. Blood 119(24):5688–5696. doi: 10.1182/blood-2011-10-386482 PubMedCrossRefGoogle Scholar
  26. 26.
    Fridman WH, Pages F, Sautes-Fridman C, Galon J (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12(4):298–306. doi: 10.1038/nrc3245 PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Mary L. Disis
    • 1
  • Yushe Dang
    • 1
  • Andrew L. Coveler
    • 1
  • Edmond Marzbani
    • 1
  • Zhong C. Kou
    • 2
  • Jennifer S. Childs
    • 1
  • Patricia Fintak
    • 1
  • Doreen M. Higgins
    • 1
  • Jessica Reichow
    • 1
  • James Waisman
    • 3
  • Lupe G. Salazar
    • 1
  1. 1.Tumor Vaccine Group, Center for Translational Medicine in Women’s HealthUniversity of WashingtonSeattleUSA
  2. 2.BioMed Immunotech, Inc.TampaUSA
  3. 3.City of HopeDuarteUSA

Personalised recommendations